Corbus Pharmaceuticals News and Activities

Corbus Pharmaceuticals is a company listed under the stock ticker CRBP (US).

View the org chart displaying its 23 main executives

Most searched biographies at Corbus Pharmaceuticals

• Yuval Cohen, Chief Executive Officer and Director
• Yong Ben, Director
• Rachelle Jacques, Chairman of the Board

Popular executive movements at Corbus Pharmaceuticals

• Nishant Saxena has joined the company as Chief Business Officer  (posted on May 21 2026).
• Brent Pfeiffenberger has joined the company as Director  (posted on May 14 2026).

Create your alert
to follow the executive moves at Corbus Pharmaceuticals.

Corbus Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Corbus Pharmaceuticals

• Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
• Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
• Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
• Press Releases
• Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
• Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
• Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026
• Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
• Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
• Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
• View more press releases Close

Social media about Corbus Pharmaceuticals

• Corbus Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Corbus Pharmaceuticals on LinkedIn, X (Twitter) & YouTube